Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the 2025 Annual General Meeting resolutions, detailing each agenda item, vote counts (agree/oppose/abstain), and final approval outcomes. Such detailed voting results from a general shareholders’ meeting match the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 Chinese
圣湘生物科技股份有限公司2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”行动方案
Annual Report Classification · 95% confidence The document is a comprehensive report detailing the company's operational performance, management strategies, financial results, governance improvements, investor relations, and future plans for the years 2025 and 2026. It includes detailed financial figures such as revenue, R&D investment, dividend policies, share repurchase and cancellation activities, and governance reforms. The document also discusses management effectiveness, innovation, investor returns, information disclosure, and governance enhancements. The length (7050 characters) and depth of content indicate it is a full report rather than a brief announcement or presentation. The content aligns with an Annual Report (10-K) as it covers a full fiscal year performance, management discussion, financial data, governance, and outlook. There is no indication that this is merely an announcement or a certification, nor is it a transcript, proxy statement, or other specific filing type. Therefore, the document is best classified as an Annual Report (10-K). FY 2025
2026-04-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司募集资金年度存放、管理与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report issued by a certified public accounting firm regarding the annual deposit, management, and actual use of raised funds by 圣湘生物科技股份有限公司 (Shengxiang Bio-tech Co., Ltd.) for the fiscal year ending December 31, 2025. It references compliance with Chinese securities regulatory rules and Shanghai Stock Exchange guidelines related to the management of raised funds. The document includes detailed financial tables about the raised funds, their usage, cash management, and related board resolutions. It is a specialized assurance report on the use of capital raised by the company, not a full annual report or earnings release. This fits the definition of an Audit Report / Information (AR), which includes standalone audit or assurance reports on specific financial or regulatory matters, excluding full annual reports. The document length (9051 characters) and content confirm it is the report itself, not just an announcement or certification letter. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-29 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2025年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (West Securities) acting as a sponsor, providing a special verification opinion on the 2025 annual fundraising funds deposit and usage situation of Shengxiang Bio-technology Co., Ltd. It includes detailed financial data on fundraising amounts, usage, cash management, and compliance with regulatory rules. The document references specific regulatory rules related to fundraising and includes an auditor's verification report conclusion. The content is focused on the annual use and management of fundraising proceeds, which aligns with a specialized audit or verification report rather than a full annual report or earnings release. The document length is 8185 characters, which is substantial and contains detailed financial and compliance information. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and results of internal or regulatory stress tests, excluding full annual reports. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2025
2026-04-29 Chinese
圣湘生物科技股份有限公司审计委员会2025年度对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report from the Audit Committee regarding the supervision of the accounting firm for the fiscal year 2025. It discusses the audit firm's qualifications, the audit process, and the committee's oversight activities. It references the audit report issued by the accounting firm but does not contain the full audit report or detailed financial statements itself. The document is 2159 characters long, which is relatively short and consistent with a standalone audit report or information document rather than a full annual report. It is not an announcement of a report publication but a substantive report on audit supervision. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2025
2026-04-29 Chinese
圣湘生物科技股份有限公司审计委员会2025年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Audit Committee 2025 Annual Performance Report" of the company. It details the audit committee's activities, meetings, evaluations of external auditors, internal audit guidance, review of financial reports, and internal control assessments for the year 2025. It is a standalone report focused on audit committee duties and audit-related oversight, not the full annual report or financial statements themselves. The document length is under 5,000 characters and it is a detailed report rather than a brief announcement or certification. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related audit committee reports. Therefore, the correct classification is AR with high confidence. FY 2025
2026-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.